The ALOFT-IPF Trial Met Its Endpoint. Real Access Is Years Away.
Bristol Myers Squibb's Phase 3 ALOFT-IPF trial met its primary endpoint October 12. The drug, admilparant, slowed lung function decline in about 1,255 adults with idiopathic pulmonary fibrosis (Investing.com, 2026, https://www.investing.com/news/company-news/bristol-myers-squibbs-admilparant-meets-phase-3-ipf-trial-goal-93CH-4943959 ). The 60 mg dose hit statistical significance at 52 weeks; the 120 mg dose slowed decline numerically but didn't reach significance. I have pulmonary fibrosis. Different flavor—mine's silica-induced, not idiopathic. Here's the gap nobody talks about: October 12, 2026 is when Bristol Myers Squibb announced the result. If they file for FDA approval in early 2027, and FDA grants standard review, that's 12 to 18 months. Call it mid-2028 for approval. Then payers write coverage policies, prior authorizations get built, pulmonologists update their treatment algorithms. For a rare condition, real-world access lags approval by another year, may...